Bedrijfsoverzicht
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical enterprise dedicated to the development of therapeutic products aimed at treating neurodegenerative and psychiatric disorders. The company operates within the healthcare sector, specifically in the biotechnology industry, where innovation focuses on advancing treatments for complex neurological conditions. Its current market capitalization stands at $3.26M, and the organization employs a team of 4 individuals. These figures indicate that Alzamend Neuro is a micro-cap entity with a very small operational footprint, suggesting that the company is likely in an early-stage development phase where capital is primarily allocated toward research and clinical trials rather than established commercial revenue generation. The minimal workforce relative to the biotech sector's typical scale further underscores its status as a pre-revenue or early-revenue stage company heavily reliant on external funding or cash reserves to sustain its clinical pipeline.
Financiële gezondheid
The company reports no revenue over the trailing twelve-month period, resulting in a net income of $-7,544,730 and an EBITDA of $-6,939,160. The substantial gap between the zero revenue and the significant net loss reveals a cost structure dominated by research and development expenditures, clinical trial costs, and general administrative expenses typical of clinical-stage biotechnology firms. Free cash flow stands at $-3,615,899, which indicates that the company is burning through cash reserves to fund its operations and development activities rather than generating positive cash flow from sales. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, reflecting the fact that without revenue, these profitability measures cannot be calculated in a traditional sense and instead highlight the company's current lack of commercial scale. The balance sheet shows $2.71M in cash and no debt, providing a conservative financial position free of leverage obligations. With a current ratio of 1.99, the company maintains adequate short-term liquidity to cover its current liabilities, although the runway is dependent on future fundraising or successful product milestones. Return on Equity is reported at -250.0% and Return on Assets at -107.0%, metrics that reveal management is currently utilizing capital to generate losses rather than positive returns, a common characteristic of high-risk clinical-stage ventures before product approval.
Waarderingsbeoordeling
Trailing P/E and forward P/E ratios are presented as N/A or -0.33 respectively, as the company does not have positive earnings to support a standard valuation multiple. The forward P/E of -0.33 suggests a negative earnings expectation for the next period, which is consistent with the company's current financial trajectory of net losses. The price-to-book ratio is 1.49, indicating that the market values the company at 1.49 times its book value, which may reflect intangible assets such as intellectual property or the potential value of the clinical pipeline not fully captured on the balance sheet. Price-to-sales and EV/EBITDA are N/A or -0.08, respectively, as the lack of revenue renders traditional sales-based valuation multiples inapplicable. The stock's 52-week trading range spans from a low of $0.85 to a high of $8.22, providing a broad context for recent price volatility. The beta value is -0.05, an unusual metric that suggests a deviation from standard market correlation models, potentially indicating price movements that are not directly synchronized with broader market indices. These valuation metrics collectively paint a picture of a high-risk, low-liquidity asset where traditional valuation frameworks are less applicable due to the absence of earnings and revenue streams.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company currently has no revenue to measure growth against. Consequently, it is impossible to determine if earnings are growing faster or slower than revenue because neither metric exists in a positive form. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company does not distribute any portion of its earnings to shareholders. Instead of paying dividends, the company reinvests its limited cash reserves and potential future earnings into its clinical pipeline and operational expansion to pursue product development goals. The overall growth and income profile is characterized by a complete absence of historical growth data and income generation, leaving shareholders exposed to the binary outcomes of future clinical trial results and regulatory approvals.